Brad Smith is a leader in the development and implementation of biomarkers, companion diagnostics and novel technologies in laboratory and clinical research. His expertise includes technical, scientific, regulatory and business aspects of biomarker use gained from 20 years of experience in basic and clinical research in academia, biotech and pharma services including 12 years of drug development at Quintiles/IQVIA and 10 years in translational medicine research at Cell Signaling Technology. Brad has also been the author of multiple basic research, translational and personalized medicine and clinical publications and patents.